A panel of experts provide an overview of BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at ...

Panelists provide an overview of the current first-line treatment options for chronic lymphocytic leukemia (CLL), discussing the role of BTK inhibitors and venetoclax plus obinutuzumab (CLL14), and ...

Please provide your email address to receive an email when new articles are posted on . Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) management demands a patient-centered approach ...

An expert on chronic lymphocytic leukemia discusses adverse effects encountered by patients who are receiving BTK inhibitors or venetoclax-based regimens. What types of adverse effects may patients ...

Josie Montegaard, MSN, AGPCNP-BC, and Yuliya Linhares, MD, conclude their discussion with advice for patients with CLL on managing their diagnosis and treatment. Yuliya Linhares, MD, discusses how ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/w7g2gd/relapsed_chronic) has announced the addition of the "Relapsed Chronic ...

Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...

Study Overview: Nurix Therapeutics, Inc. (NRIX) is currently conducting a Phase 2 clinical trial, titled A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults With ...